Interactions between NMDA- and prostaglandin receptor-mediated events in a model of inflammatory nociception.
Preadministered niflumic acid, a nonsteroidal anti-inflammatory drug (1, 3 and 9 mg/kg i.v.), dose-relatedly reduced carrageenan-evoked spinal c-Fos expression and the peripheral ankle oedema, with the highest dose reducing in parallel both parameters (55 +/- 3% reduction of carrageenan c-Fos expression, 57 +/- 13% reduction of carrageenan-evoked ankle oedema, respectively, P < 0.001 for both). Co-administration of low doses of niflumic acid and (+)-HA966, a low-efficacy partial agonist at the glycine site of the NMDA receptor (1 mg/kg i.v. + 2.5 mg/kg s.c., respectively) significantly reduced spinal c-Fos expression, this effect was significantly different from the lack of effect of niflumic acid alone or (+)-HA966 alone on spinal c-Fos expression (P < 0.01 for both drugs). Co-administered niflumic acid and (+)-HA966 did not influence the peripheral carrageenan-evoked oedema. Spinal interactions between prostaglandin-and NMDA receptor-mediated events during inflammatory nociceptive transmission are discussed.
Buritova
J
J
Physiopharmacologie du Système Nerveux, INSERM U161, Paris, France.
Chapman
V
V
Honoré
P
P
Besson
J M
JM
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002351:Carrageenan / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D007249:Inflammation / Q000139:chemically induced / Q000503:physiopathology*; D008297:Male; D009544:Niflumic Acid / Q000494:pharmacology*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D011760:Pyrrolidinones / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018690:Excitatory Amino Acid Agonists; D016760:Proto-Oncogene Proteins c-fos; D011760:Pyrrolidinones; D009544:Niflumic Acid; D002351:Carrageenan; C001369:1-hydroxy-3-amino-2-pyrrolidone